{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:53:13Z","timestamp":1789840393745,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:53:10Z","timestamp":1749599590000},"page":"419-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"Laura","family":"Boucai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ecl.2025.03.012_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00005792-197705000-00001","article-title":"Papillary thyroid carcinoma: the impact of therapy in 576 patients","volume":"56","author":"Mazzaferri","year":"1977","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.012_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-129-8-199810150-00007","article-title":"Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma","volume":"129","author":"Taylor","year":"1998","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.012_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1072-7515(03)00332-6","article-title":"Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma","volume":"197","author":"Shoup","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.012_bib5","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1210\/jc.2003-031167","article-title":"Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer","volume":"89","author":"Sawka","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.012_bib6","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.012_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.012_bib8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1089\/thy.2014.0173","article-title":"Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer","volume":"24","author":"Wang","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.012_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071625","article-title":"Site-specific metastasis and survival in papillary thyroid cancer: the importance of brain and multi-organ disease","volume":"13","author":"Toraih","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.012_bib10","first-page":"3228","article-title":"Expression of the Na+\/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes","volume":"84","author":"Lazar","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.012_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1677\/erc.1.01164","article-title":"Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes","volume":"13","author":"Di Cristofaro","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.012_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00259-001-0737-6","article-title":"Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study","volume":"29","author":"Simon","year":"2002","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.012_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03351058","article-title":"Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma","volume":"27","author":"Coelho","year":"2004","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.012_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-6614-2-8","article-title":"13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study","volume":"2","author":"Handkiewicz-Junak","year":"2009","journal-title":"Thyroid Res"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.012_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2265.2006.02515.x","article-title":"Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies","volume":"64","author":"Liu","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.012_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.13806","article-title":"The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy","volume":"89","author":"Luo","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.012_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.012_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Cell"},{"issue":"7457","key":"10.1016\/j.ecl.2025.03.012_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.012_bib20","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.012_bib21","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ecl.2025.03.012_bib22","article-title":"Characterization of subtypes of BRAF-mutant papillary thyroid cancer defined by their thyroid differentiation score","author":"Boucai","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.012_bib23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","article-title":"Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy","volume":"29","author":"Boucai","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.ecl.2025.03.012_bib24","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1038\/sj.onc.1206602","article-title":"RET\/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase","volume":"22","author":"Knauf","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.012_bib25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","article-title":"Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ecl.2025.03.012_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13044-018-0057-6","article-title":"Synergistic inhibition of MEK\/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium\/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells","volume":"11","author":"Zhang","year":"2018","journal-title":"Thyroid Res"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.012_bib28","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.012_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ecl.2017.01.014","article-title":"Molecular genetics of thyroid cancer in children and adolescents","volume":"46","author":"Bauer","year":"2017","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.012_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090723","article-title":"Thyroid cancer in the pediatric population","volume":"10","author":"Paulson","year":"2019","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.012_bib31","doi-asserted-by":"crossref","first-page":"e1683","DOI":"10.1210\/clinem\/dgaa935","article-title":"Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape","volume":"106","author":"Nies","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.012_bib32","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2025.03.012_bib33","article-title":"Larotrectinib before initial radioactive iodine therapy in pediatric trk fusion-positive papillary thyroid carcinoma: time to reconsider the treatment paradigm for distantly metastatic disease?","volume":"6","author":"Waguespack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.012_bib34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.012_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.012_bib37","first-page":"15N","article-title":"SNMMI Procedure Standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version","volume":"63","author":"Avram","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.012_bib38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.012_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.012_bib41","first-page":"1124","article-title":"MERAIODE: a phase II redifferentiation trial with trametinib and (131)I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","volume":"33","author":"Leboulleux","year":"2023","journal-title":"Thyroid"},{"issue":"13","key":"10.1016\/j.ecl.2025.03.012_bib42","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid Cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.012_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2022.0707","article-title":"Results of the SEL-I-METRY phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy","volume":"33","author":"Wadsley","year":"2023","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ecl.2025.03.012_bib45","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.012_bib46","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ecl.2025.03.012_bib48","article-title":"RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitness","author":"Krishnamoorthy","year":"2024","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.012_bib49","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1210\/jc.2018-00612","article-title":"Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine","volume":"103","author":"Jaber","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.012_bib50","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1089\/thy.2019.0143","article-title":"Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol","volume":"29","author":"Iravani","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.012_bib51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical Outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid"},{"issue":"17","key":"10.1016\/j.ecl.2025.03.012_bib52","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMc2023094","article-title":"Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer","volume":"383","author":"Groussin","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.012_bib53","first-page":"1603","article-title":"Letter to the editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer","volume":"31","author":"Groussin","year":"2021","journal-title":"Thyroid"},{"issue":"18","key":"10.1016\/j.ecl.2025.03.012_bib54","first-page":"131","article-title":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","author":"Lee","year":"2021","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.012_bib55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1089\/thy.2021.0524","article-title":"Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer","volume":"32","author":"Groussin","year":"2022","journal-title":"Thyroid"},{"issue":"9940","key":"10.1016\/j.ecl.2025.03.012_bib56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.012_bib57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:03:11Z","timestamp":1753484591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000349"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.012","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}